Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01762059 · ClinicalTrials.gov registry record · NA
Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT01762059: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01762059 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01762059, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improved glycemic control vs. usual in the outpatient environment.
Interventions
- OTHER Usual care
- DEVICE Bi-homonal Bionic Pancreas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01762059
The ClinicalTrials.gov registry entry for NCT01762059 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Usual care is the first listed.
NCT01762059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01762059 about?
NCT01762059 is a clinical study titled "Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas". This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improved glycemic control vs. usual in the outpatient environment.
What is the current status of trial NCT01762059?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2013-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01762059?
The interventions under investigation include: Usual care (OTHER), Bi-homonal Bionic Pancreas (DEVICE).
Who is sponsoring clinical trial NCT01762059?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.